September 22, 2021 | Blogs
In part two of this series about non-traditional players in the healthcare space, CBPartners dives into one company’s (Walmart) recently established partnership with a traditional pharmaceutical company (Novo Nordisk) to investigate the larger ramifications of these new entrants for key stakeholders – patients, the pharmaceutical industry, and their traditional competition.
September 8, 2021 | Blogs
In part one of this two-part series about non-traditional players in the healthcare sector, CBPartners explores the increasingly attractive market despite the risk of an expensive failed venture by analyzing the success and failures of four non-traditional players.
September 1, 2021 | Blogs
CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.
August 30, 2021 | Blogs
Verily recently announced its first major acquisition, a software platform known as SignalPath. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform.
August 26, 2021 | Blogs
Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.